Osteoporosis in Solid Organ Transplantation: Multimedia

References

1. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. Mar 1999;14(3):456-63. [Medline].

2. Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab. May 2009;94(5):1483-90. [Medline].

3. Aris RM, Neuringer IP, Weiner MA, et al. Severe osteoporosis before and after lung transplantation. Chest. May 1996;109(5):1176-83. [Medline].

4. Donovan DS Jr, Papadopoulos A, Staron RB, et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med. Jun 1998;157(6 Pt 1):1892-9. [Medline].

5. Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. Sep 1996;101(3):262-9. [Medline].

6. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. Mar 2001;16(3):581-8. [Medline].

7. Lyu DM, Zamora MR. Medical complications of lung transplantation. Proc Am Thorac Soc. Jan 15 2009;6(1):101-7. [Medline]. [Full Text].

8. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. Sep 1997;103(3):197-207. [Medline].

9. Iqbal N, Ducharme J, Desai S, et al. Status of bone mineral density in patients selected for cardiac transplantation. Endocr Pract. Sep 2008;14(6):704-12. [Medline].

10. Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. May 1997;82(5):1497-506. [Medline].

11. Shane E, Rivas MC, Silverberg SJ, et al. Osteoporosis after cardiac transplantation. Am J Med. Mar 1993;94(3):257-64. [Medline].

12. Cohen A, Addonizio LJ, Lamour JM, et al. Osteoporosis in adult survivors of adolescent cardiac transplantation may be related to hyperparathyroidism, mild renal insufficiency, and increased bone turnover. J Heart Lung Transplant. Jun 2005;24(6):696-702.

13. Manito N, Kaplinsky EJ, Roca J, Castells E, Saura E, Gomez-Hospital JA. Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule. Clin Transplant. Jun 2005;19(3):304-8. [Medline].

14. Ninkovic M, Love SA, Tom B, et al. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int. Dec 2001;69(6):321-6. [Medline].

15. Ninkovic M, Skingle SJ, Bearcroft PW, et al. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol. Aug 2000;12(8):931-5. [Medline].

16. Monegal A, Navasa M, Guanabens N, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int. Feb 1997;60(2):148-54. [Medline].

17. Compston JE, Greer S, Skingle SJ, et al. Early increase in plasma parathyroid hormone levels following liver transplantation. J Hepatol. Nov 1996;25(5):715-8. [Medline].

18. Ormarsdottir S, Ljunggren O, Mallmin H, et al. Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol. Jan 2002;14(1):43-8. [Medline].

19. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology. Jan 1995;108(1):276-83. [Medline].

20. Rosen H. Primary biliary cirrhosis and bone disease. Hepatology. Jan 1995;21(1):253-5. [Medline].

21. Pares A, Guanabens N, Alvarez L, et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology. Mar 2001;33(3):554-60. [Medline].

22. Guardiola J, Xiol X, Sallie R, et al. Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation. Ann Intern Med. Nov 16 1999;131(10):752-5. [Medline].

23. Springer JE, Cole DE, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology. Jan 2000;118(1):145-51. [Medline].

24. Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology. Aug 1991;14(2):296-300. [Medline].

25. Trautwein C, Possienke M, Schlitt HJ, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol. Sep 2000;95(9):2343-51. [Medline].

26. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. Sep 1998;28(3):695-9. [Medline].

27. Moran CE, Sosa EG, Martinez SM, et al. Bone mineral density in patients with pancreatic insufficiency and steatorrhea. Am J Gastroenterol. May 1997;92(5):867-71. [Medline].

28. Santolaria F, Gonzalez-Reimers E, Perez-Manzano JL, et al. Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol. Nov 2000;22(3):147-57. [Medline].

29. Fatemi S, Ryzen E, Flores J, et al. Effect of experimental human magnesium depletion on parathyroid hormone secretion and 1,25-dihydroxyvitamin D metabolism. J Clin Endocrinol Metab. Nov 1991;73(5):1067-72. [Medline].

30. Peris P, Pares A, Guanabens N, et al. Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol. Nov 1992;27(6):619-25. [Medline].

31. Monegal A, Navasa M, Guanabens N, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001;12(6):484-92. [Medline].

32. Vedi S, Greer S, Skingle SJ, et al. Mechanism of bone loss after liver transplantation: A histomorphometric analysis. J Bone Miner Res. Feb 1999;14(2):281-7. [Medline].

33. Hamburg SM, Piers DA, van den Berg AP, et al. Bone mineral density in the long term after liver transplantation. Osteoporos Int. 2000;11(7):600-6. [Medline].

34. Grotz WH, Mundinger FA, Gugel B, et al. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. Oct 27 1994;58(8):912-5. [Medline].

35. Nisbeth U, Lindh E, Ljunghall S, et al. Fracture frequency after kidney transplantation. Transplant Proc. Jun 1994;26(3):1764. [Medline].

36. Torres A, Machado M, Concepción MT, Martín N, Lorenzo V, Hernández D. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int. Nov 1996;50(5):1726-33. [Medline].

37. Goodman WG, Jüppner H, Salusky IB, Sherrard DJ. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int. Jan 2003;63(1):1-11. [Medline].

38. Stein MS, Packham DK, Ebeling PR, et al. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis. Oct 1996;28(4):515-22. [Medline].

39. Piraino B, Carpenter BJ, Puschett JB. Resolution of hypercalcemia and aluminum bone disease after renal transplantation. Am J Med. Nov 1988;85(5):728-30. [Medline].

40. Nordal KP, Dahl E, Halse J, et al. Aluminum metabolism and bone histology after kidney transplantation: a one-year follow-up study. J Clin Endocrinol Metab. May 1992;74(5):1140-5. [Medline].

41. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. Nov 1993;44(5):1071-7. [Medline].

42. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. Oct 2003;14(10):2669-76. [Medline].

43. Cundy T, Kanis JA, Heynen G, et al. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med. Winter 1983;52(205):67-78. [Medline].

44. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. Aug 22 1991;325(8):544-50. [Medline].

45. Nisbeth U, Lindh E, Ljunghall S, et al. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation. May 15 1999;67(9):1218-22. [Medline].

46. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int. 2000;11(5):455-9. [Medline].

47. Smets YF, van der Pijl JW, Ringers J, et al. Pattern of bone loss after simultaneous pancreas-kidney transplantation: a prospective study. Transplant Proc. Mar 1998;30(2):326. [Medline].

48. Smets YF, de Fijter JW, Ringers J, et al. Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. Kidney Int. Nov 2004;66(5):2070-6.

49. Ismail AA, Cockerill W, Cooper C, et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int. 2001;12(2):85-90. [Medline].

50. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut. Jan 2000;46 Suppl 1:i1-8. [Medline].

51. Romero DF, Buchinsky FJ, Rucinski B, et al. Rapamycin: a bone sparing immunosuppressant?. J Bone Miner Res. May 1995;10(5):760-8. [Medline].

52. Campistol JM, Holt DW, Epstein S, Gioud-Paquet M, Rutault K, Burke JT. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int. Sep 2005;18(9):1028-35. [Medline].

53. Hofbauer LC, Heufelder AE. Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab. Jul 2000;85(7):2355-63. [Medline].

54. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med. May 1998;104(5):459-69. [Medline].

55. Patel S, Kwan JT, McCloskey E, McGee G, Thomas G, Johnson D. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res. Oct 2001;16(10):1863-70. [Medline].

56. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. Jan 2 2002;287(1):47-54. [Medline].

57. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. Jul 2001;12(7):1530-7. [Medline].

58. Coates PT, Tie M, Russ GR, Mathew TH. Transient bone marrow edema in renal transplantation: a distinct post-transplantation syndrome with a characteristic MRI appearance. Am J Transplant. May 2002;2(5):467-70.

59. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res. Dec 2004;19(12):1919-32. [Medline].

60. Boncimino K, McMahon DJ, Addesso V, et al. Magnesium deficiency and bone loss after cardiac transplantation. J Bone Miner Res. Feb 1999;14(2):295-303. [Medline].

61. Levi M. Post-transplant hypophosphatemia. Kidney Int. Jun 2001;59(6):2377-87. [Medline].

62. Vlcek J, Binswanger U, Keusch G, Záruba J. Hyperparathyroidism after kidney transplantation: a retrospective case controlled study. Klin Wochenschr. Sep 16 1991;69(14):669-73. [Medline].

63. Bushinsky DA, Chabala JM, Gavrilov KL, Levi-Setti R. Effects of in vivo metabolic acidosis on midcortical bone ion composition. Am J Physiol. Nov 1999;277(5 Pt 2):F813-9.

64. Green J, Maor G. Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers. Kidney Int. Jun 2000;57(6):2258-67.

65. Langman CB, Bushinsky DA, Favus MJ, Coe FL. Ca and P regulation of 1,25(OH)2D3 synthesis by vitamin D-replete rat tubules during acidosis. Am J Physiol. Nov 1986;251(5 Pt 2):F911-8.

66. Adams JS, Wahl TO, Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism. Mar 1981;30(3):217-21. [Medline].

67. Lemann J Jr, Gray RW, Maierhofer WJ, Cheung HS. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. Dec 1985;28(6):951-8. [Medline].

68. LaCroix AZ, Wienpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. Feb 1 1990;322(5):286-90. [Medline].

69. Looker AC, Bauer DC, Chesnut CH 3rd, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000;11(6):467-80. [Medline].

70. Hodsman AB, Steer BM. Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining. J Am Soc Nephrol. Feb 1992;2(8):1318-27. [Medline].

71. Kausz AT, Antonsen JE, Hercz G, et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis. Oct 1999;34(4):688-93. [Medline].

72. Faugere MC, Malluche HH. Stainable aluminum and not aluminum content reflects bone histology in dialyzed patients. Kidney Int. Nov 1986;30(5):717-22. [Medline].

73. Dodd VA, Staron RB, Papadopoulos A, et al. Bone densitometry should be included in the evaluation of candidates for lung transplantation. J Transpl Coord. Jun 1999;9(2):119-23. [Medline].

74. Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. Oct 1998;244(4):271-92. [Medline].

75. Nishimura J, Ikuyama S. Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab. 2000;18(6):350-2. [Medline].

76. Lark RK, Lester GE, Ontjes DA, et al. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr. Mar 2001;73(3):602-6. [Medline].

77. Sambrook P. Alfacalcidol and calcitriol in the prevention of bone loss after organ transplantation. Calcif Tissue Int. Oct 1999;65(4):341-3. [Medline].

78. Talalaj M, Gradowska L, Marcinowska-Suchowierska E, Durlik M, Gaciong Z, Lao M. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc. Dec 1996;28(6):3485-7. [Medline].

79. Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufilanchas JJ, Hawkins F. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int. Feb 1997;60(2):155-9. [Medline].

80. Dequeker J, Borghs H, Van Cleemput J, et al. Transplantation osteoporosis and corticosteroid-induced osteoporosis in autoimmune diseases: experience with alfacalcidol. Z Rheumatol. 2000;59 Suppl 1:53-7.

81. De Sevaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol. Jun 2002;13(6):1608-14.

82. Schacht E, Richy F, Reginster JY. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact. Jul-Sep 2005;5(3):273-84. [Medline].

83. Giannini S, Dangel A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. Nov 2001;16(11):2111-7. [Medline].

84. Henderson K, Eisman J, Keogh A, MacDonald P, Glanville A, Spratt P. Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res. Mar 2001;16(3):565-71. [Medline].

85. Sezer S, Uyar M, Arat Z, Ozdemir FN, Haberal M. Potential effects of 1,25-dihydroxyvitamin D3 in renal transplant recipients. Transplant Proc. Sep 2005;37(7):3109-11. [Medline].

86. Spira A, Gutierrez C, Chaparro C, et al. Osteoporosis and lung transplantation: a prospective study. Chest. Feb 2000;117(2):476-81. [Medline].

87. Shane E, Rodino MA, McMahon DJ. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant. Nov 1998;17(11):1089-96. [Medline].

88. Valero MA, Loinaz C, Larrodera L, et al. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int. Jul 1995;57(1):15-9. [Medline].

89. Aris RM, Lester GE, Renner JB, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med. Sep 2000;162(3 Pt 1):941-6. [Medline].

90. Fan SL, Almond MK, Ball E, et al. Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney Int. Feb 2000;57(2):684-90. [Medline].

91. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. Mar 2003;63(3):1130-6. [Medline].

92. Bianda T, Linka A, Junga G, et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int. Aug 2000;67(2):116-21. [Medline].

93. Bishop NJ, Ninkovic M, Alexander GJ, et al. Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively. Clin Sci (Lond). Aug 1999;97(2):157-63. [Medline].

94. Cahill BC, O'Rourke MK, Parker S, et al. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation. Oct 15 2001;72(7):1251-5. [Medline].

95. Conley E, Muth B, Samaniego M, et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation. Jul 27 2008;86(2):231-7. [Medline].

96. Isoniemi H, Appelberg J, Nilsson CG, et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol. Feb 2001;34(2):299-305. [Medline].

97. Shane E. Transplantation osteoporosis. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4^th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:296-301.

98. Sezer S, Ozdemir FN, Afsar B, Colak T, Kizay U, Haberal M. Subjective global assessment is a useful method to detect malnutrition in renal transplant patients. Transplant Proc. Mar 2006;38(2):517-20. [Medline].

99. Braith RW, Magyari PM, Fulton MN, Aranda J, Walker T, Hill JA. Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. J Heart Lung Transplant. Oct 2003;22(10):1082-90. [Medline].

100. Braith RW, Magyari PM, Fulton MN, Lisor CF, Vogel SE, Hill JA. Comparison of calcitonin versus calcitonin + resistance exercise as prophylaxis for osteoporosis in heart transplant recipients. Transplantation. Apr 27 2006;81(8):1191-5. [Medline].

101. Almond MK, Kwan JT, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron. 1994;66(1):52-7. [Medline].

102. Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Scand J Gastroenterol. Mar 2003;38(3):320-7. [Medline].

103. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis. May 2003;41(5):E18.

104. Addesso V, Elmer D, Gaber AO. Bone mass in patients with type 1 diabetes mellitus awaiting simultaneous pancreas kidney transplant. Bone. 1998;23(suppl 5):588.

105. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. Oct 23 2003;349(17):1676-9; discussion 1676-9. [Medline].

106. Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. Sep 2000;109(4):267-76. [Medline].

107. Cueto-Manzano AM, Freemont AJ, Adams JE, et al. Association of sex hormone status with the bone loss of renal transplant patients. Nephrol Dial Transplant. Jun 2001;16(6):1245-50. [Medline].

108. D'Alessandro AM, Melzer JS, Pirsch JD, et al. Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery. Dec 1989;106(6):1049-55; discussion 1055-6. [Medline].

109. Dawson-Hughes B. Bone loss accompanying medical therapies. N Engl J Med. Sep 27 2001;345(13):989-91. [Medline].

110. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res. Jan 1996;11(1):1-7. [Medline].

111. Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Curr Opin Rheumatol. May 1995;7(3):255-61. [Medline].

112. Erben RG, Stangassinger M, Gartner R. Skeletal effects of low-dose cyclosporin A in aged male rats: lack of relationship to serum testosterone levels. J Bone Miner Res. Jan 1998;13(1):79-87. [Medline].

113. Faugere MC, Arnala IO, Ritz E, Malluche HH. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med. Jun 1986;107(6):481-7. [Medline].

114. Ferrari SL, Nicod LP, Hamacher J, et al. Osteoporosis in patients undergoing lung transplantation. Eur Respir J. Nov 1996;9(11):2378-82. [Medline].

115. Foundation NK 2003 K/DOQU. Foundation NK 2003 K/DOQU clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 42 (Suppl 3):S1-S202.

116. Fudman EJ. Lack of efficacy of calcitonin in preventing glucocorticoid-induced bone loss: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis. Arthritis Rheum. Aug 1997;40(8):1549. [Medline].

117. Grotz WH, Breitenfeldt MK, Braune SW, Allmann KH, Krause TM, Rump JA. Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation. Transpl Int. 2001;14(1):16-23. [Medline].

118. Grotz WH, Mundinger FA, Gugel B, et al. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation. Apr 15 1995;59(7):982-6. [Medline].

119. Grotz WH, Mundinger FA, Rasenack J, et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant. Nov 1995;10(11):2096-100. [Medline].

120. Grotz WH, Rump LC, Niessen A, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation. Oct 27 1998;66(8):1004-8. [Medline].

121. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant. Oct 2000;14(5):457-63. [Medline].

122. Hofbauer LC, Shui C, Riggs BL, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun. Jan 12 2001;280(1):334-9. [Medline].

123. Horber FF, Casez JP, Steiger U, et al. Changes in bone mass early after kidney transplantation. J Bone Miner Res. Jan 1994;9(1):1-9. [Medline].

124. Inoue T, Kawamura I, Matsuo M, et al. Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. Transplantation. Sep 15 2000;70(5):774-9. [Medline].

125. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. Sep 27 2001;345(13):941-7. [Medline].

126. Joffe I, Katz I, Jacobs T, et al. 17 beta-estradiol prevents osteopenia in the oophorectomized rat treated with cyclosporin-A. Endocrinology. Mar 1992;130(3):1578-86. [Medline].

127. Krueger BA, Trakshel GM, Sluss PM, Maines MD. Cyclosporin-mediated depression of luteinizing hormone receptors and heme biosynthesis in rat testes: a possible mechanism for decrease in serum testosterone. Endocrinology. Nov 1991;129(5):2647-54. [Medline].

128. LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. Feb 1 1990;322(5):286-90. [Medline].

129. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol. Jan 2002;97(1):58-64. [Medline].

130. Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab. Apr 2000;11(3):79-85. [Medline].

131. Meys E, Fontanges E, Fourcade N, et al. Bone loss after orthotopic liver transplantation. Am J Med. Nov 1994;97(5):445-50. [Medline].

132. Munoz-Torres M, Jodar E, Escobar-Jimenez F, et al. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif Tissue Int. May 1996;58(5):316-9. [Medline].

133. Navasa M, Monegal A, Guanabens N, et al. Bone fractures in liver transplant patients. Br J Rheumatol. Jan 1994;33(1):52-5. [Medline].

134. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. Apr 2005;45(4):638-49. [Medline].

135. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. Apr 2005;45(4):638-49. [Medline].

136. Pichette V, Bonnardeaux A, Prudhomme L, et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis. Jul 1996;28(1):105-14. [Medline].

137. Ramirez G, Narvarte J, Bittle PA, et al. Cyclosporine-induced alterations in the hypothalamic hypophyseal gonadal axis in transplant patients. Nephron. 1991;58(1):27-32. [Medline].

138. Reeves HL, Francis RM, Manas DM, et al. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg. Sep 1998;4(5):404-9. [Medline].

139. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. Mar 2004;24(2):63-70. [Medline].

140. Sahin G, Yasar NS, Sirmagul B, et al. The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study. Ren Fail. 2008;30(10):992-9. [Medline].

141. Sass DA, Bowman AR, Yuan Z, et al. Alendronate prevents cyclosporin A-induced osteopenia in the rat. Bone. Jul 1997;21(1):65-70. [Medline].

142. Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int. Jan 2004;65(1):304-9. [Medline].

143. Sezer S, Ozdemir FN, Afsar B, Colak T, Kizay U, Haberal M. Subjective global assessment is a useful method to detect malnutrition in renal transplant patients. Transplant Proc. Mar 2006;38(2):517-20. [Medline].

144. Shane E, Papadopoulos A, Staron RB, et al. Bone loss and fracture after lung transplantation. Transplantation. Jul 27 1999;68(2):220-7. [Medline].

145. Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. Sep 1996;101(3):262-9. [Medline].

146. Sharpe M, Noble S, Spencer CM. Alendronate: an update of its use in osteoporosis. Drugs. 2001;61(7):999-1039. [Medline].

147. Silverman SL. Calcitonin. Rheum Dis Clin North Am. Feb 2001;27(1):187-96. [Medline].

148. Smallwood GA, Burns D, Fasola CG, Steiber AC, Heffron TG. Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic. Transplant Proc. May 2005;37(4):1910-1. [Medline].

149. Smets YF, van der Pijl JW, de Fijter JW, et al. Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant. May 1998;13(5):1250-5. [Medline].

150. Stein B, Takizawa M, Katz I, et al. Salmon calcitonin prevents cyclosporin-A-induced high turnover bone loss. Endocrinology. Jul 1991;129(1):92-8. [Medline].

151. Stempfle HU, Werner C, Siebert U, et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation. Feb 27 2002;73(4):547-52. [Medline].

152. Toro J, Gentil MA, García R, Pérez-Valdivia MA, García Avellano E, Algarra GR. Alendronate in kidney transplant patients: a single-center experience. Transplant Proc. Apr 2005;37(3):1471-2. [Medline].

153. Umland EM, Boyce EG. Risedronate: a new oral bisphosphonate. Clin Ther. Sep 2001;23(9):1409-21. [Medline].

154. Valimaki MJ, Kinnunen K, Tahtela R, et al. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Osteoporos Int. 1999;10(2):128-36. [Medline].

155. Van Cleemput J, Daenen W, Geusens P, Dequeker P, Van De Werf F, VanHaecke J. Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Transplantation. May 27 1996;61(10):1495-9. [Medline].

156. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. Jun 2000;15(6):993-1000. [Medline].

Further Reading

Related eMedicine topics:
Fracture, Cervical Spine
Heart Transplantation [Pediatrics: Surgery]
Heart Transplantation [Transplantation]
Immunosuppression [Pediatrics: Surgery]
Immunosuppression [Transplantation]
Kidney Transplantation
Liver Transplantation [Pediatrics: Surgery]
Liver Transplantation [Transplantation]
Lower Cervical Spine Fractures and Dislocations
Lumbar Compression Fracture
Lumbar Spine Fractures and Dislocations
Lung Transplantation [Pediatrics: Surgery]
Lung Transplantation [Transplantation]
Osteoporosis [Orthopedic Surgery]
Osteoporosis [Pediatrics: General Medicine]
Osteoporosis, Involutional
Osteoporosis (Primary)
Osteoporosis (Secondary)
Pancreas Transplantation
Renal Transplantation (Medical)
Renal Transplantation (Urology)
Transplants, Heart
Transplants, Liver
Transplants, Lung
Transplants, Renal
Vertebral Fracture

Clinical guidelines:
AASLD practice guidelines: evaluation of the patient for liver transplantation. American Association for the Study of Liver Diseases - Private Nonprofit Research Organization.  2000 Jan (revised 2005 Jun).  26 pages.  NGC:004333

Clinical trials:
Effects of Zoledronic Acid Versu Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation

Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients (VITA-D)

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation (CTX)

Keywords

osteoporosis, transplantation, transplant, transplants, osteopenia, kidney transplant, liver transplant, heart transplant, lung transplant, organ transplant, bone density, bone loss, bone mineral density, organ transplantation, immunosuppressive, immunosuppressant, liver transplantation, heart transplantation, lung transplantation, kidney transplantation, kidney/pancreas transplantation

simultaneous pancreas-kidney transplantation, SPKT, low bone mass, glucocorticoid-induced osteoporosis, low body weight, estrogen deficiency, androgen deficiency, calcium deficiency, vitamin D deficiency, thyroid hormone excess, vertebral fractures, hip fractures, negative calcium balance, bone loss, osteoporotic fractures, fragility fractures, cystic fibrosis, primary biliary cirrhosis, PBC, osteogenesis imperfecta

Contributor Information and Disclosures

Author

Carmel M Fratianni, MD, FACE, Associate Professor of Clinical Medicine, Department of Internal Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Southern Illinois University School of Medicine
Carmel M Fratianni, MD, FACE is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Endocrinology, American Diabetes Association, American Thyroid Association, Endocrine Society, and Illinois State Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Steven R Gambert, MD, MACP, Chairman, Department of Medicine, Physician-in-Chief, Sinai Hospital of Baltimore; Professor of Medicine, Program Director, Internal Medicine Program, Johns Hopkins University School of Medicine
Steven R Gambert, MD, MACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physician Executives, American College of Physicians, American Geriatrics Society, Association of Professors of Medicine, Endocrine Society, and Gerontological Society of America
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Don S Schalch, MD, Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, University of Wisconsin Hospitals and Clinics
Don S Schalch, MD is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, Central Society for Clinical Research, and Endocrine Society
Disclosure: Nothing to disclose.

CME Editor

Mark Cooper, MBBS, PhD, FRACP, Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University
Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD, Professor of Medicine, St Louis University School of Medicine
George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.